Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.

Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL 3rd, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT.

Diabetologia. 2019 Dec 19. doi: 10.1007/s00125-019-05062-x. [Epub ahead of print]


Correction to: Soluble Guanylate Cyclase Stimulators and Activators.

Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP.

Handb Exp Pharmacol. 2019 Jul 5. doi: 10.1007/164_2019_249. [Epub ahead of print]


Soluble Guanylate Cyclase Stimulators and Activators.

Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP.

Handb Exp Pharmacol. 2019 Jan 29. doi: 10.1007/164_2018_197. [Epub ahead of print]


A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.

Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):564-575. doi: 10.1002/cpdd.627. Epub 2018 Nov 13.


Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.

Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT.

Nitric Oxide. 2018 Aug 1;78:72-80. doi: 10.1016/j.niox.2018.05.009. Epub 2018 May 31. Review.


Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.

Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.

J Pharmacol Exp Ther. 2018 Jun;365(3):664-675. doi: 10.1124/jpet.117.247429. Epub 2018 Apr 11.


Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.

Ranganath S, Bhandari A, Avitahl-Curtis N, McMahon J, Wachtel D, Zhang J, Leitheiser C, Bernier SG, Liu G, Tran TT, Celino H, Tobin J, Jung J, Zhao H, Glen KE, Graul C, Griffin A, Schairer WC, Higgins C, Reza TL, Mowe E, Rivers S, Scott S, Monreal A, Shea C, Bourne G, Coons C, Smith A, Tang K, Mandyam RA, Masferrer J, Liu D, Patel DV, Fretzen A, Murphy CA, Milne GT, Smythe ML, Carlson KE.

PLoS One. 2015 Nov 10;10(11):e0141330. doi: 10.1371/journal.pone.0141330. eCollection 2015.


Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.

Hama AT, Germano P, Varghese MS, Cravatt BF, Milne GT, Pearson JP, Sagen J.

PLoS One. 2014 May 2;9(5):e96396. doi: 10.1371/journal.pone.0096396. eCollection 2014.


Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.

Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM.

J Pharmacol Exp Ther. 2011 Feb;336(2):423-30. doi: 10.1124/jpet.110.169532. Epub 2010 Oct 21.


Inhibition of filamentation can be used to treat disseminated candidiasis.

Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT.

Antimicrob Agents Chemother. 2006 Oct;50(10):3312-6.


Mutations in two Ku homologs define a DNA end-joining repair pathway in Saccharomyces cerevisiae.

Milne GT, Jin S, Shannon KB, Weaver DT.

Mol Cell Biol. 1996 Aug;16(8):4189-98.


Supplemental Content

Loading ...
Support Center